Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

已收盘 07-26 16:00:00 EDT

144.24

-3.32

-2.25%

盘后143.87

-0.37-0.26%

18:49 EDT

最高148.12	最低143.31	成交量96.45万
今开147.94	昨收147.56	日振幅3.26%
总市值136.34亿	流通市值130.14亿	总股本9,452万
成交额1.39亿	换手率1.07%	流通股本9,023万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":144.24,"timestamp":1722024000000,"preClose":147.56,"halted":0,"volume":964539,"hourTrading":{"tag":"盘后","latestPrice":143.87,"preClose":144.24,"latestTime":"18:49 EDT","volume":174324,"amount":25144056.67,"timestamp":1722034162924},"delay":0,"floatShares":90226242,"shares":94523766,"eps":0.180044,"marketStatus":"已收盘","marketStatusCode":5,"change":-3.32,"latestTime":"07-26 16:00:00 EDT","open":147.94,"high":148.12,"low":143.31,"amount":139441339.11653998,"amplitude":0.032597,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.180044,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":0,"listingDate":865396800000,"adjPreClose":147.56,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":143.87,"preClose":144.24,"latestTime":"18:49 EDT","volume":174324,"amount":25144056.67,"timestamp":1722034162924},"volumeRatio":0.830426,"impliedVol":0.5086,"impliedVolPercentile":0.2778},"requestUrl":"/m/hq/s/SRPT","defaultTab":"news","newsList":[{"id":"2445049041","title":"美国研究综述-卡马斯、礼来、微策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2445049041","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445049041?lang=zh_cn&edition=full","pubTime":"2024-06-24 15:45","pubTimestamp":1719215146,"startTime":"0","endTime":"0","summary":"要闻             * Carmax Inc   ：加拿大皇家银行将其目标价从 73 美元上调至 75 美元             * 礼来   ：杰富瑞将目标价从994美元上调至1015美元             * 微策略公司  ：Canaccord Genuity将目标价从2047美元下调至1826美元             * Sharecare Inc   ：Canaccord Genuity将目标价从买入下调至持有             * 赛默飞世尔科技公司   ：加拿大皇家银行将目标价从662美元下调至660美元 以下是路透周一报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","BK4587","LU1267930573.SGD","PYCR","RGEN","SRPT","DAY","TMUS","NVDA","LU0251142724.SGD","WAL","KMX","VZ","GILD","LNG","KBH","IE00B3S45H60.SGD","DLR","COCH","TMO","SITC","MPC","LU0266512127.USD","MSTR","IE00B1BXHZ80.USD","FDS","WKHS","BK4589","PAYC","BK4579","VLO","SHCR","BK4581","CYTK","PSX","T","LU0289739699.SGD","QDEL","BK4585","LU0321505439.SGD","IFF","LU1551013342.USD","BIO","BK4588","LU1989771016.USD","PCTY","BK4578","IE00BJT1NW94.SGD","CYRX"],"gpt_icon":0},{"id":"1151498625","title":"Sarepta Therapeutics飙升40%，旗下基因疗法获扩大用途许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1151498625","media":"老虎资讯综合","labels":["movement"],"top":-1,"share":"https://www.laohu8.com/m/news/1151498625?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:45","pubTimestamp":1718981115,"startTime":"0","endTime":"0","summary":"公司宣布Elevidys获扩大用途许可，适用于4岁及以上的杜兴氏肌肉萎缩患者。","market":"us","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT"],"gpt_icon":0},{"id":"2445765135","title":"BUZZ-Sarepta 公司的杜兴氏基因疗法获 FDA 批准扩大使用范围，公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2445765135","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445765135?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:36","pubTimestamp":1718980589,"startTime":"0","endTime":"0","summary":"    6月21日 - ** Sarepta Therapeutics   的股价在早盘交易中大涨约33%，创下三年多来的新高 ** 按目前水平计算，公司市值将增加近 40 亿美元 ** 周四晚些时候，美国食品和药物管理局批准  公司的基因疗法 Elevidys 用于遗传性进行性肌肉萎缩症患者的治疗。** 包括本交易日的涨幅在内，该公司股价今年累计上涨超过68%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","LU1923622614.USD","BK4121","LU1720051108.HKD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU0557290698.USD","IE00BFTCPJ56.SGD","LU2041044095.USD","LU0882574055.USD","LU1280957306.USD","IE0034235188.USD","LU1623119135.USD","LU1854103824.USD","LU1989771016.USD","LU1791710400.SGD","LU1064131342.USD","LU1712237335.SGD","BK4566","BK4585","IE0002141913.USD","LU2357305700.SGD","CTLT","SRPT","BK4588","LU0122379950.USD","LU2264538146.SGD","LU0957791311.USD","LU2125909759.SGD","BK4530","LU0011850046.USD","LU0528227936.USD","BK4139","LU1791710582.SGD","LU1923622291.USD","IE0009355771.USD","LU1670628061.USD","LU1720051017.SGD","LU1854104046.USD","LU0114720955.EUR","LU0640476718.USD","LU1670627923.USD","LU2125909916.SGD","BK4007","LU2125909247.SGD","TMO","BK4581","IE00B2B36J28.USD","GB00BDT5M118.USD","BK4535"],"gpt_icon":0},{"id":"2445973062","title":"Sarepta 因投资者欢呼基因疗法应用范围扩大而大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2445973062","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445973062?lang=zh_cn&edition=full","pubTime":"2024-06-21 18:46","pubTimestamp":1718966785,"startTime":"0","endTime":"0","summary":"    路透6月21日 - Sarepta Therapeutics   股价周五在盘前交易中大涨约36%，原因是该公司为杜氏肌营养不良症患者提供的基因疗法获得了扩大使用范围的批准，从而在美国打开了更大的市场。Biliouris 预计，Elevidys 将成为 DMD 基因疗法的 \"主导\"，在 2027 年之前不会出现短期竞争。同时，Sarepta 公司将于美国东部时间上午 08:30 与投资者举行电话会议，讨论扩大批准范围的事宜。周五，Sarepta 公司的市盈率为 12.52，而 RegenxBio 公司的市盈率为 1.49。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RGNX","SG9999002232.USD","LU0170899867.USD","LU0122379950.USD","IE0009355771.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4581","LU0321505868.SGD","BK4505","SGXZ57979304.SGD","SRPT","SG9999001176.SGD","LU0058720904.USD","LU1023059063.AUD","BK4139","IE00B19Z3B42.SGD","BK4533","BK4592","BK4588","IE0002270589.USD","SG9999001176.USD","BK4534","LU0321505439.SGD","LU0868494617.USD","BK4585","LU0456855351.SGD","SG9999013999.USD","BK4550","IE00BLSP4452.SGD","BK4568","LU1057294990.SGD","IE00BBT3K403.USD","IE00B2B36J28.USD","LU0289739699.SGD","PFE","BK4563","IE00BLSP4239.USD","SG9999003800.SGD","SG9999002224.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","SG9999011175.SGD","IE00BJJMRZ35.SGD","LU0234572021.USD","IE00BJT1NW94.SGD","LU1066051498.USD"],"gpt_icon":0},{"id":"2445736557","title":"Sarepta(SRPT)盘前涨近34% 美FDA批准基因疗法Elevidys扩大用途许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2445736557","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445736557?lang=zh_cn&edition=full","pubTime":"2024-06-21 17:00","pubTimestamp":1718960434,"startTime":"0","endTime":"0","summary":"金吾财讯 ｜Sarepta Therapeutics(SRPT)盘前股价上扬，暂升33.87%，报165.33美元。Sarepta Therapeutics宣布Elevidys获扩大用途许可，美国食品药品管理局(FDA)批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良(DMD)患者纳入其中。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277014","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","SRPT","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4139","IE0002141913.USD","BK4585"],"gpt_icon":0},{"id":"1107582486","title":"盘前异动 | 英伟达盘前续跌超2%，Sarepta一度涨超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107582486","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1107582486?lang=zh_cn&edition=full","pubTime":"2024-06-21 16:01","pubTimestamp":1718956869,"startTime":"0","endTime":"0","summary":"分析师指出，英伟达过高的估值和缺乏经常性收入使他们的业务本身就存在风险。","market":"us","thumbnail":"https://static.tigerbbs.com/7308276753c5ff6ceaac8e2cceebffd3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/7308276753c5ff6ceaac8e2cceebffd3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BILI","SRPT","NVDA"],"gpt_icon":1},{"id":"2445368782","title":"美国研究综述-芝加哥商品交易所集团、英格索兰公司、温尼巴戈工业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2445368782","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445368782?lang=zh_cn&edition=full","pubTime":"2024-06-21 15:33","pubTimestamp":1718955232,"startTime":"0","endTime":"0","summary":"要闻 * 芝加哥商业交易所集团  ：摩根大通将其股票评级从 \"中性 \"下调至 \"减持\"。* 英格索兰公司   ：杰富瑞恢复对该公司的评级，买入；目标价110美元  * 耐克公司  ：奥本海默将其评级从 \"跑赢大盘 \"上调至 \"跑赢大盘\"。* Sarepta Therapeutics Inc   ：加拿大皇家银行将目标价从142美元上调至182美元              * Winnebago Industries Inc   ：杰富瑞将目标价从65美元下调至60美元  以下是路透周五报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CME","VTR","LU1303367103.USD","LU2023250843.SGD","BK4079","LU1861220033.SGD","LU1861220207.SGD","LU1923622291.USD","LU1548497426.USD","OHI","VITL","BK4225","JBL","IE00BFTCPJ56.SGD","BK4504","LU2098885051.SGD","LII","IR","LU2125909759.SGD","GPN","LU2347655156.SGD","LU1023059063.AUD","BK4585","CRK","LU1861215975.USD","LU1861217088.USD","BK4086","LU0889565916.HKD","SRPT","BK4588","ENPH","MSTR","JLL","BK4161","KR","LU2125909916.SGD","ITCI","LU1718418525.SGD","ISRG","BK4595","LU0417517546.SGD","NKE","LU0070302665.USD","GMS","DRI","LU2133065610.SGD","CF","WGO","IE00B2B36J28.USD","LU2023250504.SGD"],"gpt_icon":1},{"id":"2445206660","title":"Sarepta(SRPT.US)&罗氏(RHHBY.US)DMD基因疗法Elevidys获批扩展适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2445206660","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445206660?lang=zh_cn&edition=full","pubTime":"2024-06-21 11:03","pubTimestamp":1718938991,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Sarepta Therapeutics宣布，美国FDA批准其与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良患者纳入其中，这些患者确认带有DMD基因突变。对不可行走DMD患者的持续批准取决于后续验证性试验的结果。Elevidys禁用于DMD基因第8和/或第9外显子有缺失的患者。罗氏在2019年与Sarepta达成28.5亿美元的研发合作，共同开发这一基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","BK4139","BK4007","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","IE00BJJMRZ35.SGD","03165","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","SRPT"],"gpt_icon":0},{"id":"2445276910","title":"Sarepta盘后涨近33%！旗下DMD基因疗法Elevidys获批扩展适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2445276910","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445276910?lang=zh_cn&edition=full","pubTime":"2024-06-21 08:16","pubTimestamp":1718928976,"startTime":"0","endTime":"0","summary":"S智通财经APP获悉，生物技术公司Sarepta Therapeutics周四美股盘后大涨超33%。消息面上，美国食品药品管理局批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良患者纳入其中。根据加速批准途径，Sarepta承诺进行并提交一项随机对照试验的结果，以验证和确认Elevidys在不可行走DMD患者中的临床益处。罗氏在2019年与Sarepta达成28.5亿美元的研发合作，共同开发这一基因疗法。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138375.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0002141913.USD","SRPT"],"gpt_icon":1},{"id":"2445229942","title":"BUZZ-美国 FDA 批准扩大杜兴氏症基因疗法的使用范围后，Sarepta 公司业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2445229942","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445229942?lang=zh_cn&edition=full","pubTime":"2024-06-21 05:41","pubTimestamp":1718919684,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    6月20日 - ** Sarepta Therapeutics   股价在延时交易中上涨40.9%至174美元** 美国 FDA 允许 SRPT 的基因疗法扩大使用范围 (link)，用于 4 岁 及以上的 杜氏肌营养不良症患者。** 美国食品及药物管理局（ FDA）对能行走的适龄患者 给予传统批准，对不能行走的患者给予加速批准** 截至上次收盘，股价累计上涨 28.1%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","BUZZ","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","SRPT"],"gpt_icon":0},{"id":"2445722455","title":"美国 FDA 允许扩大 Sarepta 公司杜兴氏基因疗法的使用范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2445722455","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445722455?lang=zh_cn&edition=full","pubTime":"2024-06-21 05:09","pubTimestamp":1718917754,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透6月20日 - 美国食品和药物管理局周四批准 Sarepta Therapeutics公司的  基因疗法用于所有四岁及四岁以上  能行走的杜氏肌营养不良症患者  (DMD)。     去年6月，美国食品和药物管理局（FDA）根据加速审批程序批准了这种疗法--这是第一种治疗DMD的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","SRPT"],"gpt_icon":0},{"id":"2444119454","title":"Sarepta Therapeutics, Inc.盘中异动 急速下挫5.01%报116.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444119454","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444119454?lang=zh_cn&edition=full","pubTime":"2024-06-18 03:59","pubTimestamp":1718654372,"startTime":"0","endTime":"0","summary":"北京时间2024年06月18日03时59分，Sarepta Therapeutics, Inc.股票出现异动，股价大幅下挫5.01%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.45%。其相关个股中，Mustang Bio, Inc.、Scinai Immunotherapeutics Ltd、Azitra Inc涨幅较大，Scinai Immunotherapeutics Ltd、Mustang Bio, Inc.、Longeveron Inc.较为活跃，换手率分别为5145.51%、3881.62%、204.42%，振幅较大的相关个股有Mustang Bio, Inc.、Azitra Inc、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为524.62%、89.22%、79.35%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240618035932aef54d2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240618035932aef54d2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","IE00BJJMRZ35.SGD","LENZ","IE00B2B36J28.USD","IE0002141913.USD","SRPT"],"gpt_icon":0},{"id":"2443083688","title":"BUZZ-分析师称辉瑞基因疗法试验失败巩固了公司地位，Sarepta 公司业绩上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2443083688","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443083688?lang=zh_cn&edition=full","pubTime":"2024-06-13 20:54","pubTimestamp":1718283250,"startTime":"0","endTime":"0","summary":" (更新)    6月13日 - ** Sarepta Therapeutics  股价盘前上涨3.6%，报124美元，此前竞争对手辉瑞  的杜氏基因疗法在一项后期研究中失败。** 周三晚些时候，辉瑞公司表示， ，其治疗肌肉萎缩性疾病的实验性疗法未能达到改善 4 至 7 岁能行走男孩的运动相关功能的目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","SG9999002232.USD","BK4585","LU0289739699.SGD","SG9999003800.SGD","LU0321505868.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU0170899867.USD","LU0234572021.USD","BUZZ","SG9999011175.SGD","IE0002141913.USD","LU0456855351.SGD","BK4581","IE00BJJMRZ35.SGD","PFE","BK4007","BK4139","BK4550","LU1057294990.SGD","LU0321505439.SGD","LU1066051498.USD","LU0868494617.USD","LU1066053197.SGD","LU0122379950.USD","IE00BBT3K403.USD","IE0002270589.USD","BK4533","IE00BJT1NW94.SGD","SGXZ57979304.SGD","SRPT","LU0058720904.USD","BK4588","SG9999013999.USD","IE00B19Z3B42.SGD","BK4592","IE00BFTCPJ56.SGD","BK4534","IE00BLSP4452.SGD","IE0009355771.USD","IE00BLSP4239.USD","BK4568","SG9999002224.SGD","IE00B19Z3581.USD","SG9999001176.USD"],"gpt_icon":0},{"id":"2443505899","title":"BUZZ-分析师称辉瑞基因疗法试验失败 \"巩固 \"了竞争对手 Sarepta 的地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2443505899","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443505899?lang=zh_cn&edition=full","pubTime":"2024-06-13 18:29","pubTimestamp":1718274550,"startTime":"0","endTime":"0","summary":"** 我们认为投资者对整个项目的预期非常低\"--古根海姆经纪公司 ** 竞争对手 Sarepta Therapeutics 的  基因疗法 Elevidys 去年获得了加速审批，美国 FDA 将在今年 6 月 21 日前就传统审批做出决定 。* 视为对 Elevidys 的真正竞争威胁\"--经纪公司威廉-布莱尔说。** BMO Capital Markets 券商表示，辉瑞的试验失败 \"对 Elevidys 而言是一个利好消息，该公司有望利用扩大的先发优势和强大的患者/支付者/处方者网络\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","BK4550","IE0002270589.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","BK4568","IE00BBT3K403.USD","PFE","LU1066051498.USD","LU0321505439.SGD","LU0058720904.USD","BK4588","LU0289739699.SGD","SG9999013999.USD","IE00BLSP4452.SGD","LU0234572021.USD","IE00BJT1NW94.SGD","SG9999011175.SGD","BK4007","LU1023059063.AUD","SG9999001176.USD","IE00B19Z3B42.SGD","LU0868494617.USD","IE00B2B36J28.USD","LU0170899867.USD","SG9999002232.USD","IE00BLSP4239.USD","BK4592","BK4581","IE0009355771.USD","LU1057294990.SGD","LU1066053197.SGD","LU0122379950.USD","LU0456855351.SGD","BK4139","IE0002141913.USD","BK4585","SG9999001176.SGD","IE00B19Z3581.USD","BK4533","SG9999002224.SGD","BUZZ","SRPT","BK4534","IE00BFTCPJ56.SGD","SG9999003800.SGD"],"gpt_icon":0},{"id":"2440921256","title":"Sarepta Therapeutics宣布根据纳斯达克上市规则5635 (C) (4) 提供激励性补助","url":"https://stock-news.laohu8.com/highlight/detail?id=2440921256","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440921256?lang=zh_cn&edition=full","pubTime":"2024-06-01 05:56","pubTimestamp":1717192566,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布根据纳斯达克上市规则5635 (C) (4) 提供激励性补助","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406010556079581949b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406010556079581949b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJJMRZ35.SGD","SQQQ","SRPT","LU0320765646.SGD","LENZ","MNQmain","NQmain","QLD","BK4504","LU0130102774.USD","LU0310800965.SGD","BK4585","BK4207","LU0128525689.USD",".IXIC","LU0648001328.SGD","LU1267930227.SGD","BK4139","BK4566","IE0002141913.USD","LU0052756011.USD","NDX","IE00BSNM7G36.USD","LU0098860793.USD","IE00B2B36J28.USD","IE0009355771.USD","TQQQ","BK4007","LU0980610538.SGD","LU1201861249.SGD","LU1162221912.USD","PSQ","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","QID","ARTL","BK4588","QQQ","BK4534"],"gpt_icon":0},{"id":"2440094770","title":"Sarepta Therapeutics, Inc.盘中异动 临近收盘股价大涨5.01%报130.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440094770","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440094770?lang=zh_cn&edition=full","pubTime":"2024-06-01 03:54","pubTimestamp":1717185293,"startTime":"0","endTime":"0","summary":"北京时间2024年06月01日03时54分，Sarepta Therapeutics, Inc.股票出现波动，股价大幅拉升5.01%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.27%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。该信息摘要如下：Sarepta Therapeutics获Piper Sandler首次覆盖，给予增持评级, 目标价157.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240601035453968112ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240601035453968112ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJT1NW94.SGD","SRPT","BK4585","LENZ","IE00B2B36J28.USD","BK4139","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD"],"gpt_icon":0},{"id":"2439969442","title":"Sarepta Therapeutics(SRPT.US)获Piper Sandler首次覆盖，给予增持评级, 目标价157.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2439969442","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439969442?lang=zh_cn&edition=full","pubTime":"2024-05-31 18:16","pubTimestamp":1717150587,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics(SRPT.US)获Piper Sandler首次覆盖，给予增持评级, 目标价157.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405311816319f0a38cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405311816319f0a38cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SRPT"],"gpt_icon":0},{"id":"2439623951","title":"BUZZ-Sarepta Therapeutics 因纳入标准普尔中型市值指数而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2439623951","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439623951?lang=zh_cn&edition=full","pubTime":"2024-05-30 22:35","pubTimestamp":1717079729,"startTime":"0","endTime":"0","summary":"    5月30日 - ** Sarepta Therapeutics  股价周四早盘上涨6.1%，报123.32美元，该公司将于下周加入标准普尔中型企业400指数<.IDX** 股价创4月24日以来最大单日涨幅** 根据标准普尔道琼斯指数公司的公告，SRPT将从6月1日（周一）起取代Shockwave Medical Inc  在IDX中的地位。 ** Shockwave 被强生公司  以 130 亿美元收购  ** 伦敦证券交易所集团数据显示，Sarepta 目前市值约为 117 亿美元** 本月早些时候，Sarepta称 ，美国FDA将在6月21日之前对其肌肉萎缩症基因疗法Elevidys的传统批准申请作出决定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","LU1032955483.USD","LU0053671581.USD","LU0795875086.SGD","LU1244550221.USD","LU1732799900.SGD","LU1935042991.SGD","LU1057294990.SGD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU1244550577.SGD","IE00BFTCPJ56.SGD","LU1261432733.SGD","LU1506573853.SGD","LU2468319806.SGD","LU0882574055.USD","LU1280957306.USD","IE00BJT1NW94.SGD","LU1066051498.USD","LU0889566641.SGD","BK4585","LU1732800096.USD","LU2065731478.USD","SRPT","IE00B19Z3B42.SGD","BK4550","BK4588","LU1196500208.SGD","LU0912757837.SGD","LU1244550494.USD","SG9999001440.SGD","LU1221951129.SGD","SWAV","LU0792757196.USD","LU0122379950.USD","LU1059921491.USD","LENZ","BK4139","BK4592","IE0009355771.USD","LU0114720955.EUR","LU0640476718.USD","BK4532","BK4007","JNJ","LU1032466523.USD","LU2602419157.SGD","IE00B19Z3581.USD","BK4581","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2439428246","title":"Sarepta Therapeutics, Inc.盘中异动 快速上涨5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439428246","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439428246?lang=zh_cn&edition=full","pubTime":"2024-05-30 21:30","pubTimestamp":1717075824,"startTime":"0","endTime":"0","summary":"北京时间2024年05月30日21时30分，Sarepta Therapeutics, Inc.股票出现异动，股价快速拉升5.76%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。该信息摘要如下：Sarepta Therapeutics Inc：加拿大皇家银行从跑赢大盘下调行业表现；将目标价从157美元下调至142美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024053021302596810d16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024053021302596810d16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","SRPT"],"gpt_icon":0},{"id":"2439682536","title":"Sarepta Therapeutics 将加入标普中型股 400","url":"https://stock-news.laohu8.com/highlight/detail?id=2439682536","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439682536?lang=zh_cn&edition=full","pubTime":"2024-05-30 05:55","pubTimestamp":1717019747,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics 将加入标普中型股 400","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405300555499f01cfd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405300555499f01cfd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","LENZ","IE00BFTCPJ56.SGD","SRPT","IE0002141913.USD","BK4139","IE0009355771.USD","BK4585","IE00BJJMRZ35.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":0.0263},{"period":"1month","weight":-0.0664},{"period":"3month","weight":0.1459},{"period":"6month","weight":0.2428},{"period":"1year","weight":0.4171},{"period":"ytd","weight":0.5302}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司，专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术，并通过与战略合作伙伴的合作，该公司开发了多个获批产品，用于治疗杜氏肌营养不良症，并正在为广泛的疾病和紊乱开发潜在的候选治疗药物，包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050901},{"month":2,"riseRate":0.666667,"avgChangeRate":0.055118},{"month":3,"riseRate":0.5,"avgChangeRate":0.024789},{"month":4,"riseRate":0.333333,"avgChangeRate":0.013657},{"month":5,"riseRate":0.75,"avgChangeRate":0.176958},{"month":6,"riseRate":0.75,"avgChangeRate":0.09879},{"month":7,"riseRate":0.333333,"avgChangeRate":0.001358},{"month":8,"riseRate":0.75,"avgChangeRate":0.094027},{"month":9,"riseRate":0.583333,"avgChangeRate":0.152276},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.101643},{"month":11,"riseRate":0.75,"avgChangeRate":0.091344},{"month":12,"riseRate":0.583333,"avgChangeRate":0.019375}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况